688796 百奥赛图
已收盘 03-05 15:00:01
资讯
新帖
简况
百奥赛图(688796)披露证券变动月报表,3月4日股价下跌0.43%
证券之星 · 03-04 17:13
百奥赛图(688796)披露证券变动月报表,3月4日股价下跌0.43%
每周股票复盘:百奥赛图(688796)2025年净利增416.37%
证券之星 · 03-01
每周股票复盘:百奥赛图(688796)2025年净利增416.37%
百奥赛图达成临床里程碑:IDEAYA首创B7h3/Ptk7双特异性Top1 ADC药物Ide034完成首例患者给药
美股速递 · 02-28
百奥赛图达成临床里程碑:IDEAYA首创B7h3/Ptk7双特异性Top1 ADC药物Ide034完成首例患者给药
港股异动 | 百奥赛图-B(02315)再涨超5% 预计去年归母净利同比增长416.37% 海外市场持续拓展
智通财经 · 02-27
港股异动 | 百奥赛图-B(02315)再涨超5% 预计去年归母净利同比增长416.37% 海外市场持续拓展
百奥赛图(688796)披露2025年年度业绩快报公告,2月26日股价上涨8.15%
证券之星 · 02-26
百奥赛图(688796)披露2025年年度业绩快报公告,2月26日股价上涨8.15%
百奥赛图2025年业绩快报:归母净利润1.73亿元 增长416.37%
财中社 · 02-26
百奥赛图2025年业绩快报:归母净利润1.73亿元 增长416.37%
百奥赛图-B午前涨超6% IDE034首例患者给药触发500万美元里程碑款项
新浪港股 · 02-26
百奥赛图-B午前涨超6% IDE034首例患者给药触发500万美元里程碑款项
百奥赛图(688796)披露2026年第一次临时股东会决议公告,2月24日股价下跌5.62%
证券之星 · 02-24
百奥赛图(688796)披露2026年第一次临时股东会决议公告,2月24日股价下跌5.62%
每周股票复盘:百奥赛图(688796)股东会通过补选非执行董事议案
证券之星 · 02-15
每周股票复盘:百奥赛图(688796)股东会通过补选非执行董事议案
百奥赛图-B(02315):刘弘康获委任为非执行董事
智通财经 · 02-12
百奥赛图-B(02315):刘弘康获委任为非执行董事
百奥赛图-B午后涨超6%
每日经济新闻 · 02-11
百奥赛图-B午后涨超6%
港股异动 | 百奥赛图-B(02315)午后涨超6% 25年业绩预告亮眼 对外授权打开长期增长天花板
智通财经 · 02-11
港股异动 | 百奥赛图-B(02315)午后涨超6% 25年业绩预告亮眼 对外授权打开长期增长天花板
每周股票复盘:百奥赛图(688796)补选刘弘康为非执行董事
证券之星 · 02-08
每周股票复盘:百奥赛图(688796)补选刘弘康为非执行董事
百奥赛图(688796)披露补选非执行董事候选人公告,2月4日股价下跌1.94%
证券之星 · 02-04
百奥赛图(688796)披露补选非执行董事候选人公告,2月4日股价下跌1.94%
港股异动 | 百奥赛图-B(02315)再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力
智通财经 · 02-04
港股异动 | 百奥赛图-B(02315)再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力
港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权
智通财经 · 02-03
港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权
港股百奥赛图盘中涨超24%!预计全年营收增长约40%,纯利增长约400%
老虎资讯综合 · 01-30
港股百奥赛图盘中涨超24%!预计全年营收增长约40%,纯利增长约400%
港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%
智通财经 · 01-30
港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%
百奥赛图(688796)披露2025年年度业绩预盈公告,1月29日股价下跌3.37%
证券之星 · 01-29
百奥赛图(688796)披露2025年年度业绩预盈公告,1月29日股价下跌3.37%
百奥赛图-B(02315)发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元 同比增加384.26%到443.88%
智通财经 · 01-29
百奥赛图-B(02315)发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元 同比增加384.26%到443.88%
加载更多
公司概况
公司名称:
百奥赛图(北京)医药科技股份有限公司
所属行业:
研究和试验发展
上市日期:
2025-12-10
主营业务:
百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。
发行价格:
26.68
{"stockData":{"symbol":"688796","market":"SH","secType":"STK","nameCN":"百奥赛图","latestPrice":71.07,"timestamp":1772694001000,"preClose":69.69,"halted":0,"volume":790141,"delay":0,"changeRate":0.0198,"floatShares":35887600,"shares":447000000,"eps":0,"marketStatus":"已收盘","change":1.38,"latestTime":"03-05 15:00:01","open":70,"high":72.99,"low":70,"amount":56734100,"amplitude":0.0429,"askPrice":71.07,"askSize":1,"bidPrice":71.05,"bidSize":4,"shortable":0,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772760600000},"marketStatusCode":5,"adr":0,"adjPreClose":69.69,"symbolType":"stock_kcb","openAndCloseTimeList":[[1772674200000,1772681400000],[1772686800000,1772694000000]],"highLimit":76.66,"lowLimit":62.72,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":446898420,"isCdr":false,"pbRate":32.55,"roa":"--","roe":"12.61%","epsLYR":0.08,"committee":-0.637931,"marketValue":31761000000,"turnoverRate":0.022,"status":0,"afterMarket":{"amount":0,"volume":0,"close":71.07,"buyVolume":0,"sellVolume":0,"time":1772696037558,"indexStatus":"已收盘 03-05 15:30:00","preClose":69.69},"hkstockBrief":{"symbol":"02315","market":"HK","secType":"STK","nameCN":"百奥赛图-B","latestPrice":45.18,"timestamp":1772698105006,"preClose":45.2,"halted":0,"volume":974000,"delay":0,"premium":"-43.78"},"floatMarketCap":2551000000},"requestUrl":"/m/hq/s/688796","defaultTab":"news","newsList":[{"id":"2616753361","title":"百奥赛图(688796)披露证券变动月报表,3月4日股价下跌0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616753361","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616753361?lang=zh_cn&edition=full","pubTime":"2026-03-04 17:13","pubTimestamp":1772615629,"startTime":"0","endTime":"0","summary":"截至2026年3月4日收盘,百奥赛图报收于69.69元,较前一交易日下跌0.43%,最新总市值为311.44亿元。该股当日开盘69.0元,最高70.68元,最低68.17元,成交额达8249.1万元,换手率为3.32%。近日,百奥赛图(北京)医药科技股份有限公司披露《证券变动月报表》,提交截至2026年2月28日的股份变动情况。公告显示,公司H股和A股的法定/注册股本及已发行股份均无变动。公司确认已符合香港联交所规定的公众持股量要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030400030016.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["161027","BK0216","688796"],"gpt_icon":0},{"id":"2616184551","title":"每周股票复盘:百奥赛图(688796)2025年净利增416.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2616184551","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616184551?lang=zh_cn&edition=full","pubTime":"2026-03-01 02:43","pubTimestamp":1772304190,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘,百奥赛图报收于76.75元,较上周的75.6元上涨1.52%。本周,百奥赛图2月26日盘中最高价报79.88元,股价触及近一年最高点。本周关注点来自业绩披露要点:百奥赛图2025年归属净利润同比增长416.37%。公司公告汇总百奥赛图(北京)医药科技股份有限公司发布2025年年度业绩快报,营业总收入137,880.84万元,同比增长40.63%;归属于母公司所有者的净利润17,319.98万元,同比增长416.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100000975.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"gpt_icon":0},{"id":"1173470828","title":"百奥赛图达成临床里程碑:IDEAYA首创B7h3/Ptk7双特异性Top1 ADC药物Ide034完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=1173470828","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173470828?lang=zh_cn&edition=full","pubTime":"2026-02-28 08:01","pubTimestamp":1772236877,"startTime":"0","endTime":"0","summary":"百奥赛图宣布达成重要临床进展,其合作伙伴IDEAYA Biosciences研发的首创B7h3/Ptk7双特异性Top1抗体偶联药物Ide034,已顺利完成I期临床试验的首例患者给药。这一里程碑标志着该创新疗法正式进入临床验证阶段,为后续开发奠定基础。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2614009429","title":"港股异动 | 百奥赛图-B(02315)再涨超5% 预计去年归母净利同比增长416.37% 海外市场持续拓展","url":"https://stock-news.laohu8.com/highlight/detail?id=2614009429","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614009429?lang=zh_cn&edition=full","pubTime":"2026-02-27 09:50","pubTimestamp":1772157052,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B再涨超5%,截至发稿,涨5.09%,报55.75港元,成交额663.51万港元。消息面上,2月26日,百奥赛图-B发布2025年度业绩快报,预计集团2025年营业收入约为13.79亿元同比增长40.63%;实现归属于本公司所有者的净利润人民币1.73亿元,同比增长416.37%;实现归属于本公司所有者的扣除非经常性损益的净利润人民币1.16亿元,同比增长405.39%。本集团总资产人民币37.24亿元,较期初增加 54.20%;归属于本公司的所有者权益人民币21.75亿元,较期初增加160.76%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1407970.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK4588","BK0216","VT","02315","BK1161","BK4585","688796"],"gpt_icon":0},{"id":"2614256610","title":"百奥赛图(688796)披露2025年年度业绩快报公告,2月26日股价上涨8.15%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614256610","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614256610?lang=zh_cn&edition=full","pubTime":"2026-02-26 23:09","pubTimestamp":1772118554,"startTime":"0","endTime":"0","summary":"截至2026年2月26日收盘,百奥赛图报收于77.51元,较前一交易日上涨8.15%,最新总市值为346.39亿元。该股当日开盘71.07元,最高79.88元,最低69.03元,成交额达2.11亿元,换手率为7.92%。近日,百奥赛图(北京)医药科技股份有限公司披露2025年年度业绩快报公告。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022600037709.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"gpt_icon":0},{"id":"2614013270","title":"百奥赛图2025年业绩快报:归母净利润1.73亿元 增长416.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614013270","media":"财中社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614013270?lang=zh_cn&edition=full","pubTime":"2026-02-26 16:39","pubTimestamp":1772095190,"startTime":"0","endTime":"0","summary":"2月26日,百奥赛图(688796/02315)发布公告,2025年业绩快报显示,公司实现营业总收入13.79亿元,同比增长40.63%;归母净利润为1.73亿元,同比增长416.37%。具体数据如下:截至报告期末,公司总资产37.24亿元,较期初增加54.20%;归母净资产21.75亿元,较期初增加160.76%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602263655351359.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["688796"],"gpt_icon":0},{"id":"2614060185","title":"百奥赛图-B午前涨超6% IDE034首例患者给药触发500万美元里程碑款项","url":"https://stock-news.laohu8.com/highlight/detail?id=2614060185","media":"新浪港股","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614060185?lang=zh_cn&edition=full","pubTime":"2026-02-26 11:51","pubTimestamp":1772077860,"startTime":"0","endTime":"0","summary":" 百奥赛图-B午前涨超6%,截至发稿,股价上涨6.49%,现报53.35港元,成交额2847.94万港元。根据双方签署的期权与许可协议,IDE034首例患者给药将触发IDEAYA向百奥赛图支付500万美元的里程碑款项。 据悉,IDE034是一款潜在同类首创的双靶点B7H3/PTK7 TOP1 ADC,由百奥赛图自主开发,并于2024年7月授权给IDEAYA公司。此次IND获批标志着双方合作迈入重要里程碑,为推进IDE034后续的临床开发奠定基础,同时彰显了百奥赛图在双抗ADC发现与开发领域的技术实力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-02-26/doc-inhpckam0549901.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK1161","688796","BK0216","02315"],"gpt_icon":0},{"id":"2613300794","title":"百奥赛图(688796)披露2026年第一次临时股东会决议公告,2月24日股价下跌5.62%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613300794","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613300794?lang=zh_cn&edition=full","pubTime":"2026-02-24 17:50","pubTimestamp":1771926626,"startTime":"0","endTime":"0","summary":"截至2026年2月24日收盘,百奥赛图报收于71.35元,较前一交易日下跌5.62%,最新总市值为318.86亿元。该股当日开盘75.04元,最高76.31元,最低71.0元,成交额达1.82亿元,换手率为6.95%。百奥赛图(北京)医药科技股份有限公司于2026年2月12日召开2026年第一次临时股东会,审议通过了关于补选公司第二届董事会非执行董事的议案。出席会议的股东共718人,代表有表决权股份总数的59.1381%。议案获得普通决议通过,其中A股中小投资者表决情况已单独计票。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400033799.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2611456281","title":"每周股票复盘:百奥赛图(688796)股东会通过补选非执行董事议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2611456281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2611456281?lang=zh_cn&edition=full","pubTime":"2026-02-15 02:14","pubTimestamp":1771092854,"startTime":"0","endTime":"0","summary":"截至2026年2月13日收盘,百奥赛图报收于75.6元,较上周的70.96元上涨6.54%。本周,百奥赛图2月12日盘中最高价报78.59元。本周关注点公司公告汇总:股东会审议通过补选第二届董事会非执行董事议案,同意股份数占比99.9935%。本次股东会于2026年2月12日以现场和网络投票方式召开,审议通过了《关于补选公司第二届董事会非执行董事的议案》。表决结果显示,同意股份数占出席会议股东所持有效表决权的99.9935%,议案获得通过。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026021500000691.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2610925508","title":"百奥赛图-B(02315):刘弘康获委任为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2610925508","media":"智通财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610925508?lang=zh_cn&edition=full","pubTime":"2026-02-12 20:23","pubTimestamp":1770899039,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B(02315)发布公告,经股东于临时股东会上批准,刘弘康先生已获委任为非执行董事,自2026年2月12日起生效并直至第二届董事会任期届满之日止。董事会于2026年1月27日举行的董事会会议上审议及批准委任刘先生待获股东批准委任为非执行董事后担任董事会审计委员会及战略发展委员会成员。任期自批准选举刘先生为第二届董事会非执行董事之日起生效,直至第二届董事会任期届满止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404838.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","688796","BK0216","BK1161"],"gpt_icon":0},{"id":"2610189988","title":"百奥赛图-B午后涨超6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610189988","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610189988?lang=zh_cn&edition=full","pubTime":"2026-02-11 14:10","pubTimestamp":1770790224,"startTime":"0","endTime":"0","summary":"每经AI快讯,2月11日,百奥赛图-B(02315.HK)午后涨超6%,截至发稿涨6.33%,报52.95港元,成交额3402.99万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202602113647795275.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202602113647795275.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1161","02315","688796","BK0216"],"gpt_icon":0},{"id":"2610898830","title":"港股异动 | 百奥赛图-B(02315)午后涨超6% 25年业绩预告亮眼 对外授权打开长期增长天花板","url":"https://stock-news.laohu8.com/highlight/detail?id=2610898830","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610898830?lang=zh_cn&edition=full","pubTime":"2026-02-11 13:43","pubTimestamp":1770788609,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B午后涨超6%,截至发稿,涨6.33%,报52.95港元,成交额3402.99万港元。消息面上,百奥赛图近期发布2025年度业绩预告,预计全年实现营收约13.69亿元至13.89亿元,同比增幅为39.61%到41.65%;预计实现归母净利润约为1.62亿元-1.82亿元,同比大幅增长384.26%至443.88%。国联民生证券发布研报称,受益于模式动物及临床前CRO业务的创新优势、“千鼠万抗”计划支持下的抗体平台优势,百奥赛图2025年业绩表现亮眼。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404066.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4585","BK1161","VXUS","VT","02315","688796","BK0216","BK4588"],"gpt_icon":0},{"id":"2609264055","title":"每周股票复盘:百奥赛图(688796)补选刘弘康为非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2609264055","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609264055?lang=zh_cn&edition=full","pubTime":"2026-02-08 03:15","pubTimestamp":1770491712,"startTime":"0","endTime":"0","summary":"截至2026年2月6日收盘,百奥赛图报收于70.96元,较上周的72.59元下跌2.25%。股本股东变化:截至2026年1月31日,公司H股和A股已发行股份均无变动。百奥赛图(北京)医药科技股份有限公司因非执行董事魏义良辞职,拟补选刘弘康为第二届董事会非执行董事候选人,任期至本届董事会任期届满。刘弘康的任职资格符合相关法律法规及公司章程规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020800001177.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2608985203","title":"百奥赛图(688796)披露补选非执行董事候选人公告,2月4日股价下跌1.94%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608985203","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608985203?lang=zh_cn&edition=full","pubTime":"2026-02-04 22:30","pubTimestamp":1770215437,"startTime":"0","endTime":"0","summary":"截至2026年2月4日收盘,百奥赛图报收于70.25元,较前一交易日下跌1.94%,最新总市值为313.95亿元。该股当日开盘71.64元,最高72.5元,最低68.64元,成交额达1.49亿元,换手率为5.91%。近日,百奥赛图(北京)医药科技股份有限公司披露《2026年第一次临时股东会会议资料》。公告显示,因公司非执行董事魏义良辞职,董事会拟补选刘弘康为第二届董事会非执行董事候选人,任期至本届董事会任期届满。刘弘康的任职资格符合相关法律法规及公司章程规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026020400041641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0216","688796"],"gpt_icon":0},{"id":"2608582353","title":"港股异动 | 百奥赛图-B(02315)再涨超5% 主业景气带动收入高增 机构看好公司长期增长潜力","url":"https://stock-news.laohu8.com/highlight/detail?id=2608582353","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608582353?lang=zh_cn&edition=full","pubTime":"2026-02-04 15:28","pubTimestamp":1770190106,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B再涨超5%,截至发稿,涨5.41%,报47.96港元,成交额6986.85万港元。国联民生证券认为,创新动物模型及临床前CRO业务高景气带动收入高增。该行指出,2025年以来,公司与多家国内外头部药企达成对外授权,并有多条管线获得IND批准,随着授权管线的推进,公司有望获得里程碑付款等收入,进一步打开增长天花板。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401499.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["VXUS","BK0216","02315","VT","BK4585","BK4588","BK1161","688796"],"gpt_icon":0},{"id":"2608481958","title":"港股异动 | 百奥赛图-B(02315)再涨超10% 全年纯利预增最多4.4倍 公司已达成多项重磅对外授权","url":"https://stock-news.laohu8.com/highlight/detail?id=2608481958","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608481958?lang=zh_cn&edition=full","pubTime":"2026-02-03 11:02","pubTimestamp":1770087766,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B再涨超10%,截至发稿,涨8.58%,报45.56港元,成交额6619.52万港元。消息面上,百奥赛图近期发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元,同比增加384.26%到443.88%。公告称,受益于海外市场的持续拓展,叠加国内生物医药行业的复苏回暖,公司营业收入实现高速增长。高壁垒的技术优势保障业务毛利维持高位,精益化管理举措进一步推动运营效率提升,公司盈利水平得以快速提高。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400891.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK4588","02315","BK0216","VT","BK4585","688796"],"gpt_icon":0},{"id":"1124857080","title":"港股百奥赛图盘中涨超24%!预计全年营收增长约40%,纯利增长约400%","url":"https://stock-news.laohu8.com/highlight/detail?id=1124857080","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1124857080?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:57","pubTimestamp":1769738220,"startTime":"0","endTime":"0","summary":"1月30日,$百奥赛图-B$盈喜后涨超24%,预计全年营收增长约40%,纯利增长约400%。消息面上,$百奥赛图$发布2025年度业绩预告,预计全年实现营收约13.69亿元-13.89亿元,较上年同期增加3.89亿元至4.08亿元,同比增幅为39.61%到41.65%;预计实现归母净利润约为1.62亿元-1.82亿元,较上年同期增加1.29亿元至1.49亿元,同比大幅增长384.26%至443.88%。","market":"hk","thumbnail":"https://static.tigerbbs.com/9bedac14febdf709f4cca99ceb4b91b1","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/9bedac14febdf709f4cca99ceb4b91b1"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"1a25853d795dfd507082cf4888ca5511","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0216","02315","688796","BK4588","VT","BK4585"],"gpt_icon":0},{"id":"2607906696","title":"港股异动 | 百奥赛图-B(02315)盈喜后涨近13% 预计全年营收增长约40% 纯利增长约400%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607906696","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607906696?lang=zh_cn&edition=full","pubTime":"2026-01-30 09:43","pubTimestamp":1769737415,"startTime":"0","endTime":"0","summary":"智通财经APP获悉,百奥赛图-B盈喜后涨近13%,截至发稿,涨8.82%,报47.88港元,成交额2771.5万港元。消息面上,百奥赛图发布2025年度业绩预告,预计全年实现营收约13.69亿元-13.89亿元,较上年同期增加3.89亿元至4.08亿元,同比增幅为39.61%到41.65%;预计实现归母净利润约为1.62亿元-1.82亿元,较上年同期增加1.29亿元至1.49亿元,同比大幅增长384.26%至443.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":"1a25853d795dfd507082cf4888ca5511","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399551.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688796","VT","02315"],"gpt_icon":0},{"id":"2607036271","title":"百奥赛图(688796)披露2025年年度业绩预盈公告,1月29日股价下跌3.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607036271","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607036271?lang=zh_cn&edition=full","pubTime":"2026-01-29 23:00","pubTimestamp":1769698847,"startTime":"0","endTime":"0","summary":"截至2026年1月29日收盘,百奥赛图报收于66.58元,较前一交易日下跌3.37%,最新总市值为297.54亿元。该股当日开盘68.9元,最高69.69元,最低66.35元,成交额达1.07亿元,换手率为4.41%。近日,百奥赛图(北京)医药科技股份有限公司发布2025年年度业绩预盈公告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012900044105.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688796","BK0216"],"gpt_icon":0},{"id":"2607704829","title":"百奥赛图-B(02315)发布2025年度业绩预告,预期归母净利润1.62亿元至1.82亿元 同比增加384.26%到443.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607704829","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607704829?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:34","pubTimestamp":1769675699,"startTime":"0","endTime":"0","summary":"智通财经APP讯,百奥赛图-B 发布2025年度业绩预告,经公司财务部门初步测算,预计本集团2025年年度实现营业收入人民币13.69亿元至人民币13.89亿元,与上年同期相比,将增加人民币3.88亿元至人民币4.08亿元,同比增加39.61%至41.65%。预计本集团2025年年度实现归属于母公司所有者的净利润人民币1.62亿元至人民币1.82亿元,与上年同期相比,将增加人民币1.29亿元到人民币1.49亿元,同比增加384.26%到443.88%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399134.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02315","688796"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772732407271,"stockEarnings":[{"period":"1week","weight":-0.0831},{"period":"1month","weight":-0.008},{"period":"3month","weight":1.6638},{"period":"ytd","weight":0.3511}],"compareEarnings":[{"period":"1week","weight":-0.0092},{"period":"1month","weight":0.01},{"period":"3month","weight":0.0527},{"period":"6month","weight":0.0777},{"period":"1year","weight":0.2294},{"period":"ytd","weight":0.0352}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"百奥赛图(北京)医药科技股份有限公司","boardCode":"AI0073","boardName":"研究和试验发展","stockholders":"28549人","perCapita":"1257股","listingDate":"2025-12-10","address":"北京市大兴区中关村科技园区大兴生物医药产业基地宝参南街12号院","registeredCapital":"44689万元","survey":" 百奥赛图(北京)医药科技股份有限公司是一家主要从事药物开发业务及临床前研究的公司。该公司通过五个分部开展业务。基因编辑服务分部提供基于动物和细胞的定制化基因编辑服务。临床前药理药效评估分部提供用于药物疗效和毒性评估的临床前药理学服务。模式动物销售分部培育和销售外用和内用模式动物。抗体开发分部利用抗体发现平台识别有可能成为候选药物的抗体。创新药开发分部研发创新药,专注肿瘤学和自身免疫性疾病治疗。","listedPrice":26.68},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"百奥赛图,688796,百奥赛图股票,百奥赛图股票老虎,百奥赛图股票老虎国际,百奥赛图行情,百奥赛图股票行情,百奥赛图股价,百奥赛图股市,百奥赛图股票价格,百奥赛图股票交易,百奥赛图股票购买,百奥赛图股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"百奥赛图(688796)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供百奥赛图(688796)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}